SG11201708822PA - Imidazopyrazinones as pde1 inhibitors - Google Patents

Imidazopyrazinones as pde1 inhibitors

Info

Publication number: SG11201708822PA
Authority: SG; Singapore
Prior art keywords: imidazopyrazinones; pde1 inhibitors; pde1; inhibitors
Prior art date: 2015-04-30

Application number

SG11201708822PA

Inventor

Jan Kehler

Lars Kyhn Rasmussen

Morten Langgård

Mikkel Jessing

Paulo Jorge Vieira Vital

Karsten Juhl

Original Assignee

H Lundbeck As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-04-30

Filing date

2016-04-29

Publication date

2017-11-29

2016-04-29 Application filed by H Lundbeck As filed Critical H Lundbeck As

2017-11-29 Publication of SG11201708822PA publication Critical patent/SG11201708822PA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

SG11201708822PA 2015-04-30 2016-04-29 Imidazopyrazinones as pde1 inhibitors SG11201708822PA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DKPA201500261		2015-04-30
DKPA201500666		2015-10-29
DKPA201600202		2016-04-04
PCT/EP2016/059583 WO2016174188A1 (en)	2015-04-30	2016-04-29	Imidazopyrazinones as pde1 inhibitors

Publications (1)

Publication Number	Publication Date
SG11201708822PA true SG11201708822PA (en)	2017-11-29

Family

ID=55910242

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201708822PA SG11201708822PA (en)	2015-04-30	2016-04-29	Imidazopyrazinones as pde1 inhibitors

Country Status (41)

Country	Link
US (4)	US20160318939A1 (en)
EP (1)	EP3288944B1 (en)
JP (1)	JP6663930B2 (en)
KR (1)	KR102605759B1 (en)
CN (1)	CN107531714B (en)
AU (1)	AU2016256573B2 (en)
BR (1)	BR112017023182B1 (en)
CA (1)	CA2983563A1 (en)
CL (1)	CL2017002719A1 (en)
CO (1)	CO2017010399A2 (en)
CY (1)	CY1121806T1 (en)
DK (1)	DK3288944T3 (en)
DO (1)	DOP2017000254A (en)
EA (1)	EA031946B1 (en)
EC (1)	ECSP17072228A (en)
ES (1)	ES2735422T3 (en)
GE (1)	GEP20207058B (en)
GT (1)	GT201700223A (en)
HK (1)	HK1252098B (en)
HR (1)	HRP20191180T1 (en)
HU (1)	HUE044244T2 (en)
IL (1)	IL255316B (en)
JO (1)	JO3627B1 (en)
LT (1)	LT3288944T (en)
MA (1)	MA41977B1 (en)
ME (1)	ME03414B (en)
MX (1)	MX2017013785A (en)
MY (1)	MY182382A (en)
PE (1)	PE20180121A1 (en)
PH (1)	PH12017501990B1 (en)
PL (1)	PL3288944T3 (en)
PT (1)	PT3288944T (en)
RS (1)	RS59051B1 (en)
RU (1)	RU2712219C2 (en)
SG (1)	SG11201708822PA (en)
SI (1)	SI3288944T1 (en)
TN (1)	TN2017000428A1 (en)
TW (1)	TWI695838B (en)
UA (1)	UA123050C2 (en)
WO (1)	WO2016174188A1 (en)
ZA (1)	ZA201706847B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201629064A (en)	2014-10-10	2016-08-16	Ｈ朗德貝克公司	Triazolopyrainones as PDE1 inhibitors
JO3627B1 (en)	2015-04-30	2020-08-27	H Lundbeck As	Imidazopyrazinones as PDE1 inhibitors
TWI729109B (en)	2016-04-12	2021-06-01	丹麥商Ｈ朗德貝克公司	1,5-DIHYDRO-4H-PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-c]PYRIDIN-4-ONES AS PDE1 INHIBITORS
ES2967489T3 (en)	2016-10-18	2024-04-30	H Lundbeck As	Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
EP3532053A1 (en)	2016-10-28	2019-09-04	H. Lundbeck A/S	Combination treatments comprising administration of imidazopyrazinones
WO2018078038A1 (en) *	2016-10-28	2018-05-03	H. Lundbeck A/S	Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
JOP20190126A1 (en)	2016-12-22	2019-05-28	H Lundbeck As	Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
KR102590848B1 (en)	2016-12-28	2023-10-19	다트 뉴로사이언스, 엘엘씨	Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
JP7254078B2 (en)	2017-11-27	2023-04-07	ダート・ニューロサイエンス・エルエルシー	Substituted furanopyrimidine compounds as PDE1 inhibitors
AR113926A1 (en) *	2017-12-14	2020-07-01	H Lundbeck As	DERIVATIVES OF 1H-PYRAZOLE [4,3-B] PYRIDINES
US11535611B2 (en)	2017-12-20	2022-12-27	H. Lundbeck A/S	Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB973361A (en)	1960-05-11	1964-10-28	Ciba Ltd	Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (en)	1997-03-11	1998-09-17	Bayer Ag	1,5-dihydro-pyrazolo [3,4-d] pyrimidinone derivatives
MY144532A (en)	2001-08-20	2011-09-30	Lundbeck & Co As H	Novel method for down-regulation of amyloid
DE10238722A1 (en)	2002-08-23	2004-03-11	Bayer Ag	Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives
DE10238723A1 (en)	2002-08-23	2004-03-11	Bayer Ag	Phenyl substituted pyrazolyprimidines
DE10238724A1 (en)	2002-08-23	2004-03-04	Bayer Ag	New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance
JP2006525966A (en)	2003-05-09	2006-11-16	バイエル・ヘルスケア・アクチェンゲゼルシャフト	6-cyclylmethyl- and 6-alkylmethyl substituted pyrazolopyrimidines
BRPI0509576A (en) *	2004-04-02	2007-05-29	Osi Pharm Inc	compound, method of treating a patient having a condition that is mediated by protein kinase activity, and, pharmaceutical composition
WO2006068978A2 (en) *	2004-12-21	2006-06-29	Takeda Pharmaceutial Company Limited	Dipeptidyl peptidase inhibitors
EP1919287A4 (en) *	2005-08-23	2010-04-28	Intra Cellular Therapies Inc	Organic compounds for treating reduced dopamine receptor signalling activity
US8012936B2 (en)	2006-03-29	2011-09-06	New York University	Tau fragments for immunotherapy
WO2008070095A1 (en)	2006-12-05	2008-06-12	Intra-Cellular Therapies, Inc.	Novel uses
NZ580904A (en)	2007-05-11	2012-02-24	Pfizer	Amino-heterocyclic compounds for inhibiting pde9
EP2227472A1 (en)	2007-11-30	2010-09-15	Elbion Gmbh	Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en)	2008-04-02	2014-05-12	Бьорингер Ингельхайм Интернациональ Гмбх	1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PE20110383A1 (en) *	2008-09-08	2011-07-15	Boehringer Ingelheim Int	PYRAZOLOPYRIMIDINONES AS INHIBITORS OF PHOSPHODIESTERASE 9A (PDE9A)
SG171777A1 (en)	2008-12-06	2011-07-28	Intra Cellular Therapies Inc	Organic compounds
TWI404721B (en)	2009-01-26	2013-08-11	Pfizer	Amino-heterocyclic compounds
CA2765099A1 (en)	2009-06-10	2010-12-16	New York University	Phosphorylated tau peptide for use in the treatment of tauopathy
US9434730B2 (en)	2010-05-31	2016-09-06	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
PL3339323T3 (en)	2010-08-12	2020-05-18	Eli Lilly And Company	Anti-n3pglu amyloid beta peptide antibodies and uses thereof
CN103313988B (en) *	2010-09-20	2016-06-08	论坛医药有限公司	Imidazo-triazine ketonic compound
EP2619204A4 (en)	2010-09-21	2014-08-27	Merck Sharp & Dohme	Triazolopyrazinones as p2x7 receptor antagonists
JO3089B1 (en)	2010-11-19	2017-03-15	H Lundbeck As	Imidazole derivatives as PDE10A enzyme inhibitors
US9499610B2 (en)	2011-04-08	2016-11-22	H. Lundbeck A/S	Antibodies specific to pyroglutamated Aβ
US10561656B2 (en)	2011-06-10	2020-02-18	Intra-Cellular Therapies, Inc.	Organic compounds
JP2015531401A (en) *	2011-10-10	2015-11-02	ハー・ルンドベック・アクチエゼルスカベット	PDE9I having imidazopyrazinone skeleton
US9434733B2 (en)	2012-01-26	2016-09-06	H. Lundbeck A/S	PDE9 inhibitors with imidazo triazinone backbone
JP2013166727A (en)	2012-02-16	2013-08-29	Dainippon Sumitomo Pharma Co Ltd	Dihydroimidazo pyrazinone derivative
EP2861603B1 (en)	2012-06-18	2018-12-19	Dart NeuroScience (Cayman) Ltd	6-Benzyl-6H-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and 6-benzyl-[1,2,4]triazolo[1,5-c]pteridin-5(6H)-one derivatives as PDE1 inhibitors for treating e.g. neurological disorders
JP6437519B2 (en)	2013-03-15	2018-12-12	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	Organic compounds
JP5783297B2 (en)	2013-08-06	2015-09-24	株式会社デンソー	Mechanical quantity sensor
MA39225A1 (en)	2014-02-19	2017-04-28	H Lundbeck As	2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines used as bace1 inhibitors in the treatment of alzheimer's disease
JP5797815B1 (en)	2014-06-27	2015-10-21	細田建設株式会社	Post-installed anchor and its construction method
WO2016042775A1 (en)	2014-09-18	2016-03-24	Sunovion Pharmaceuticals Inc.	Tricyclic derivative
US20160083391A1 (en)	2014-09-18	2016-03-24	Sunovion Pharmaceuticals Inc.	Tricyclic piperazine derivative
US20160083400A1 (en)	2014-09-18	2016-03-24	Sunovion Pharmaceuticals Inc.	Tricyclic guanidine derivative
TW201629064A (en)	2014-10-10	2016-08-16	Ｈ朗德貝克公司	Triazolopyrainones as PDE1 inhibitors
MA40941A (en)	2014-11-10	2017-09-19	H Lundbeck As	2-AMINO-5,5-DIFLUORO-6- (FLUOROMETHYL) -6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS
CR20170187A (en)	2014-11-10	2018-02-01	H Lundbeck As	2-Amino-3,5-difluoro-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for the treatment of Alzheimer's disease
JO3458B1 (en)	2014-11-10	2020-07-05	H Lundbeck As	2-Amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors
JP2018508555A (en)	2015-03-16	2018-03-29	大日本住友製薬株式会社	Bicyclic imidazolo derivatives
TW201643167A (en)	2015-04-22	2016-12-16	Ｈ朗德貝克公司	Imidazotriazinones as PDE1 inhibitors
JO3627B1 (en)	2015-04-30	2020-08-27	H Lundbeck As	Imidazopyrazinones as PDE1 inhibitors
JO3711B1 (en)	2015-07-13	2021-01-31	H Lundbeck As	Antibodies specific for hyperphosphorylated tau and methods of use thereof
MX2018001699A (en)	2015-08-12	2018-05-07	H Lundbeck As	2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetr ahydropyridins as bace1 inhibitors.
TWI609870B (en)	2016-02-12	2018-01-01	美國禮來大藥廠	Pde1 inhibitor
TWI729109B (en)	2016-04-12	2021-06-01	丹麥商Ｈ朗德貝克公司	1,5-DIHYDRO-4H-PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-c]PYRIDIN-4-ONES AS PDE1 INHIBITORS
ES2967489T3 (en)	2016-10-18	2024-04-30	H Lundbeck As	Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
WO2018078038A1 (en)	2016-10-28	2018-05-03	H. Lundbeck A/S	Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
EP3532053A1 (en)	2016-10-28	2019-09-04	H. Lundbeck A/S	Combination treatments comprising administration of imidazopyrazinones

2016
- 2016-04-26 JO JOP/2016/0081A patent/JO3627B1/en active
- 2016-04-27 TW TW105113074A patent/TWI695838B/en active
- 2016-04-29 LT LTEP16720101.1T patent/LT3288944T/en unknown
- 2016-04-29 SI SI201630319T patent/SI3288944T1/en unknown
- 2016-04-29 EP EP16720101.1A patent/EP3288944B1/en active Active
- 2016-04-29 US US15/142,116 patent/US20160318939A1/en not_active Abandoned
- 2016-04-29 RU RU2017137514A patent/RU2712219C2/en active
- 2016-04-29 ME MEP-2019-186A patent/ME03414B/en unknown
- 2016-04-29 KR KR1020177030665A patent/KR102605759B1/en active IP Right Grant
- 2016-04-29 HU HUE16720101 patent/HUE044244T2/en unknown
- 2016-04-29 MY MYPI2017001597A patent/MY182382A/en unknown
- 2016-04-29 PL PL16720101T patent/PL3288944T3/en unknown
- 2016-04-29 AU AU2016256573A patent/AU2016256573B2/en active Active
- 2016-04-29 JP JP2017556677A patent/JP6663930B2/en active Active
- 2016-04-29 WO PCT/EP2016/059583 patent/WO2016174188A1/en active Application Filing
- 2016-04-29 MX MX2017013785A patent/MX2017013785A/en active IP Right Grant
- 2016-04-29 DK DK16720101.1T patent/DK3288944T3/en active
- 2016-04-29 TN TNP/2017/000428A patent/TN2017000428A1/en unknown
- 2016-04-29 UA UAA201710625A patent/UA123050C2/en unknown
- 2016-04-29 RS RS20190893A patent/RS59051B1/en unknown
- 2016-04-29 MA MA41977A patent/MA41977B1/en unknown
- 2016-04-29 PT PT16720101T patent/PT3288944T/en unknown
- 2016-04-29 BR BR112017023182-4A patent/BR112017023182B1/en active IP Right Grant
- 2016-04-29 SG SG11201708822PA patent/SG11201708822PA/en unknown
- 2016-04-29 ES ES16720101T patent/ES2735422T3/en active Active
- 2016-04-29 PE PE2017002342A patent/PE20180121A1/en unknown
- 2016-04-29 CA CA2983563A patent/CA2983563A1/en active Pending
- 2016-04-29 GE GEAP201614615A patent/GEP20207058B/en unknown
- 2016-04-29 EA EA201792157A patent/EA031946B1/en not_active IP Right Cessation
- 2016-04-29 CN CN201680023903.9A patent/CN107531714B/en active Active
2017
- 2017-06-06 US US15/615,380 patent/US10011606B2/en active Active
- 2017-10-10 ZA ZA2017/06847A patent/ZA201706847B/en unknown
- 2017-10-12 CO CONC2017/0010399A patent/CO2017010399A2/en unknown
- 2017-10-24 GT GT201700223A patent/GT201700223A/en unknown
- 2017-10-26 CL CL2017002719A patent/CL2017002719A1/en unknown
- 2017-10-27 EC ECIEPI201772228A patent/ECSP17072228A/en unknown
- 2017-10-29 IL IL255316A patent/IL255316B/en unknown
- 2017-10-30 DO DO2017000254A patent/DOP2017000254A/en unknown
- 2017-10-30 PH PH12017501990A patent/PH12017501990B1/en unknown
2018
- 2018-06-07 US US16/002,116 patent/US10858362B2/en active Active
- 2018-09-05 HK HK18111408.3A patent/HK1252098B/en unknown
2019
- 2019-07-01 HR HRP20191180TT patent/HRP20191180T1/en unknown
- 2019-07-15 CY CY20191100751T patent/CY1121806T1/en unknown
2020
- 2020-10-26 US US17/079,951 patent/US11472810B2/en active Active

Also Published As

Publication number	Publication date
RU2712219C2 (en)	2020-01-27
HK1252098A1 (en)	2019-05-17
MX2017013785A (en)	2018-03-27
GEP20207058B (en)	2020-01-27
LT3288944T (en)	2019-07-25
JP6663930B2 (en)	2020-03-13
PH12017501990A1 (en)	2018-03-26
ME03414B (en)	2020-01-20
US20210238182A1 (en)	2021-08-05
MA41977A (en)	2018-07-23
ZA201706847B (en)	2019-01-30
TWI695838B (en)	2020-06-11
US20160318939A1 (en)	2016-11-03
KR102605759B1 (en)	2023-11-23
WO2016174188A1 (en)	2016-11-03
EA031946B1 (en)	2019-03-29
UA123050C2 (en)	2021-02-10
MA41977B1 (en)	2019-08-30
CA2983563A1 (en)	2016-11-03
EP3288944B1 (en)	2019-06-12
US10011606B2 (en)	2018-07-03
EA201792157A1 (en)	2018-03-30
IL255316A0 (en)	2017-12-31
EP3288944A1 (en)	2018-03-07
ES2735422T3 (en)	2019-12-18
GT201700223A (en)	2018-12-19
JO3627B1 (en)	2020-08-27
AU2016256573B2 (en)	2019-11-21
HUE044244T2 (en)	2019-10-28
RU2017137514A (en)	2019-05-31
RU2017137514A3 (en)	2019-07-17
PH12017501990B1 (en)	2018-03-26
AU2016256573A1 (en)	2017-12-14
US20190062335A1 (en)	2019-02-28
CL2017002719A1 (en)	2018-04-20
CO2017010399A2 (en)	2018-01-05
JP2018514552A (en)	2018-06-07
CN107531714B (en)	2019-07-19
US10858362B2 (en)	2020-12-08
TN2017000428A1 (en)	2019-04-12
DK3288944T3 (en)	2019-07-22
MY182382A (en)	2021-01-22
KR20170140216A (en)	2017-12-20
PE20180121A1 (en)	2018-01-18
US20170291903A1 (en)	2017-10-12
US11472810B2 (en)	2022-10-18
BR112017023182A2 (en)	2018-10-02
HK1252098B (en)	2020-02-07
BR112017023182B1 (en)	2023-10-31
CY1121806T1 (en)	2020-07-31
ECSP17072228A (en)	2018-02-28
CN107531714A (en)	2018-01-02
RS59051B1 (en)	2019-08-30
IL255316B (en)	2021-10-31
DOP2017000254A (en)	2018-01-15
SI3288944T1 (en)	2019-08-30
PT3288944T (en)	2019-07-19
TW201700477A (en)	2017-01-01
HRP20191180T1 (en)	2019-10-04
PL3288944T3 (en)	2019-11-29

Publication	Publication Date	Title
HK1249097A1 (en)	2018-10-26	Imidazotriazinones as pde1 inhibitors
IL259560A (en)	2018-07-31	Inhibitors of the menin-mll interaction
IL251420A0 (en)	2017-05-29	Triazolopyrazinones as pde1 inhibitors
ZA201804070B (en)	2021-10-27	Eif4-a-inhibiting compounds and methods related thereto
IL246785A0 (en)	2016-08-31	Benzimidazol-2-amines as midh1 inhibitors
HK1252098A1 (en)	2019-05-17	Imidazopyrazinones as pde1 inhibitors
HK1226398A1 (en)	2017-09-29	Benzimidazol-2-amines as midh1 inhibitors
GB201508950D0 (en)	2015-07-01	Methods
IL265139B (en)	2021-08-31	Dopamine-b-hydroxylase inhibitors
GB201612860D0 (en)	2016-09-07	Inhibitors
GB201501004D0 (en)	2015-03-04	Inhibitors
HK1251572A1 (en)	2019-02-01	Triaza-spirodecanones as ddr1 inhibitors
IL246230A0 (en)	2016-08-02	Quinazolin-thf-amines as pde1 inhibitors
IL248078B (en)	2018-11-29	Halogenated quinazolin-thf-amines as pde1 inhibitors
GB201508927D0 (en)	2015-07-01	Methods
HK1232214A1 (en)	2018-01-05	Hexahydrofuropyrroles as pde1 inhibitors pde1
GB201520949D0 (en)	2016-01-13	Inhibitors
GB201509696D0 (en)	2015-07-22	Methods